Yes to an extent as the price that will ultimately be able to be charged will be dependent on many factors including how well bisantrene works as a cardioprotective anticancer agent. Of course as investors you need to have some idea of the likely pricing, so this is why we shared the Triangle report.
I should mention that the Triangle report was from primary market research undertaken for internal purposes as we want to ensure that we developed bisantrene in a way that met a true large-scale market need. It is all too easy to just focus on the science and end up developing a drug that has a very limited market. Decision made early in development can make or break the commercial success of a new drug. Making sure you get the positioning of your drug right is difficult and even the largest pharma companies struggle with this process.
- Forums
- ASX - By Stock
- RAC
- Ann: Race releases complete cardio-protection data & video
Ann: Race releases complete cardio-protection data & video, page-228
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.61 |
Change
-0.040(2.42%) |
Mkt cap ! $274.1M |
Open | High | Low | Value | Volume |
$1.65 | $1.70 | $1.60 | $229.6K | 139.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 129 | $1.61 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.65 | 2839 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 129 | 1.610 |
1 | 8000 | 1.595 |
1 | 5000 | 1.590 |
1 | 1158 | 1.585 |
4 | 18253 | 1.570 |
Price($) | Vol. | No. |
---|---|---|
1.650 | 2839 | 1 |
1.700 | 5000 | 1 |
1.715 | 1100 | 1 |
1.750 | 1500 | 1 |
1.770 | 6060 | 1 |
Last trade - 16.10pm 04/07/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |